Key result
Arterial hypertension is linked to high thrombosis risk in low-risk polycythemia vera.
Why the study?
Low-risk polycythemia vera patients with arterial hypertension have a high incidence of thrombosis that may require more intensive therapy.
Does the addition of cytoreductive drugs to phlebotomy, aspirin, and ACE inhibitors reduce the incidence of thrombosis in low-risk polycythemia vera patients with arterial hypertension?
Does the addition of cytoreductive drugs to phlebotomy, aspirin, and ACE inhibitors reduce the incidence of thrombosis in low-risk polycythemia vera patients with arterial hypertension?
Answers are grounded in this paper and cite their sources.
Low-risk polycythemia vera patients with arterial hypertension may require more intensive therapy, such as cytoreductive drugs, to reduce thrombosis risk.
low-risk PV patients with arterial hypertension represent a subgroup in which a more intensive therapy should be explored in prospective studies designed to examine whether the addition of cytoreductive drugs to phlebotomy and aspirin and ACE inhibitors may reduce the still high incidence of thrombosis.
No takes yet. Share an insight, caveat, or question.
Barbui et al. (2016) studied this question. Arterial hypertension in low-risk polycythemia vera patients is associated with a high incidence of thrombosis, suggesting a need for more intensive cytoreductive therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: